Status: Recruiting
VS-6766+Abema+Fulv in Met HR+/HER- BC
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Participants needed: 63
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Adrienne G. WaksUpdated: Apr 30, 2026Locations: 3
Eligibility criteria
Participants must have histologically or cytologically confirmed hormone recepto... [+34]
Participants with active brain metastases or with known carcinomatous meningitis... [+23]